Radiosynthesis, optimization and pharmacokinetic study of the (99m)Tc-labeled human epidermal growth factor receptor 2 affibody molecule probe (99m)Tc-(HE)(3)Z(HER2:V2)

To prepare a single-photon molecular probe easily labeled with (99m)Tc for evaluating the expression status of the human epidermal growth factor receptor 2 (HER2) receptor in ovarian cancer. MATERIALS AND METHODS: The HEHEHE tag was added to the amino terminus of the affibody Z(HER2:V2) by the method of gene recombinant expression, and a new affibody was synthesized which was easy to be labeled with (99m)Tc. The newly prepared affibody was labeled with (99m)Tc, and pharmacokinetic studies were carried out. RESULTS: A new affibody (HE)(3)Z(HER2:V2) was prepared by the method of gene recombination and expression, which is easy to be labeled with (99m)Tc. The (99m)Tc labeling of the affibody can reach about 95% at 90°C. The pharmacokinetic study has shown that the (99m)Tc-labeled molecular probe has a fast clearance time in the blood and little side effect, which may be a promising single-photon emission computed tomography (SPECT) imaging agent. CONCLUSION: The affibody (HE)(3)Z(HER2:V2) is easy to be labeled with (99m)Tc, has a high yield and has a suitable half-life in vivo, which is suitable for the next step in ovarian cancer model imaging research.